Discontinued — last reported Q3 '20
Eli Lilly Available-for-Sale Debt Securities - Fair Value (Maturing Within 1 Year) decreased by 84.7% to $12.70M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 88.0%, from $105.90M to $12.70M.
afs_debt_securities_fair_value_maturing_within_1y| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $21.60M | $21.60M | $98.90M | $102.10M | $97.70M | $76.00M | $86.10M | $88.20M | $83.70M | $97.40M | $105.90M | $102.60M | $83.00M | $12.70M |
| QoQ Change | — | +0.0% | +357.9% | +3.2% | -4.3% | -22.2% | +13.3% | +2.4% | -5.1% | +16.4% | +8.7% | -3.1% | -19.1% | -84.7% |
| YoY Change | — | — | — | +372.7% | +352.3% | -23.2% | -15.7% | -9.7% | +10.1% | +13.1% | +20.1% | +22.6% | -14.8% | -88.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.